{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:47:01Z","timestamp":1792079221233,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Biochem Biotechnol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12010-026-05919-z","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:27:14Z","timestamp":1789543634000},"page":"8934-8949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Potential of Pirfenidone in Adenine-Induced Chronic Kidney Disease: An Integrated Experimental and In Silico Study"],"prefix":"10.1007","volume":"198","author":[{"given":"Al Darraji","family":"Raad kareem Alwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad","family":"Oraibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teeb Ali","family":"Al-Saady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Almukram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safaa","family":"Halool Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hamza AlShammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa A.","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musaab","family":"Dauelbait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz Muhammad","family":"Zohaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar A.","family":"Almohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"5919_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41572-024-00589-9;SUBJMETA","volume":"11","author":"P Romagnani","year":"2025","unstructured":"Romagnani, P., Agarwal, R., Chan, J. C. N., Levin, A., Kalyesubula, R., Karam, S., Nangaku, M., Rodr\u00edguez-Iturbe, B., & Anders, H. J. (2025). Chronic Kidney Disease. Nature Reviews Disease Primers, 11, 1\u201323. https:\/\/doi.org\/10.1038\/S41572-024-00589-9;SUBJMETA","journal-title":"Nature Reviews Disease Primers"},{"key":"5919_CR2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/JCH.14186","volume":"23","author":"S Wilson","year":"2021","unstructured":"Wilson, S., Mone, P., Jankauskas, S. S., Gambardella, J., & Santulli, G. (2021). Chronic Kidney Disease: Definition, Updated Epidemiology, Staging, and Mechanisms of Increased Cardiovascular Risk. The Journal of Clinical Hypertension, 23, 831. https:\/\/doi.org\/10.1111\/JCH.14186","journal-title":"The Journal of Clinical Hypertension"},{"key":"5919_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/17512433.2025.2468954","volume":"18","author":"PI Georgianos","year":"2025","unstructured":"Georgianos, P. I., Kourtidou, C., Leivaditis, K., Kollias, A., & Liakopoulos, V. (2025). Can We Optimize the Use of Renin-Angiotensin-System Inhibitors in Patients with Chronic Kidney Disease? Expert Review of Clinical Pharmacology, 18, 185\u2013188. https:\/\/doi.org\/10.1080\/17512433.2025.2468954","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"5919_CR4","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1038\/S41440-025-02146-7;KWRD","volume":"48","author":"D Ichikawa","year":"2025","unstructured":"Ichikawa, D., Kawarazaki, W., Saka, S., Kanaoka, T., Ohnishi, H., Arima, H., & Shibata, S. (2025). Efficacy of Renin-Angiotensin System Inhibitors, Calcium Channel Blockers, and Diuretics in Hypertensive Patients with Diabetes: Subgroup Analysis Based on Albuminuria in a Systematic Review and Meta-Analysis. Hypertension Research, 48, 1880\u20131890. https:\/\/doi.org\/10.1038\/S41440-025-02146-7;KWRD","journal-title":"Hypertension Research"},{"key":"5919_CR5","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.15420\/CFR.2021.30","volume":"8","author":"A Aimo","year":"2022","unstructured":"Aimo, A., Spitaleri, G., Nieri, D., Tavanti, L. M., Meschi, C., Panichella, G., Lup\u00f3n, J., Pistelli, F., Carrozzi, L., Bayes-Genis, A., et al. (2022). Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond. Cardiac Failure Review, 8, e12. https:\/\/doi.org\/10.15420\/CFR.2021.30","journal-title":"Cardiac Failure Review"},{"key":"5919_CR6","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1007\/S12247-023-09763-0\/METRICS","volume":"18","author":"KR Dudhat","year":"2023","unstructured":"Dudhat, K. R., Patel, H. V., Mori, D. D., & Design (2023). Development, and In Vitro Characterization of Pirfenidone-Loaded Biodegradable Nanoparticles for Idiopathic Pulmonary Fibrosis. Journal of Pharmaceutical Innovation, 18, 1908\u20131925. https:\/\/doi.org\/10.1007\/S12247-023-09763-0\/METRICS","journal-title":"Journal of Pharmaceutical Innovation"},{"key":"5919_CR7","doi-asserted-by":"publisher","first-page":"121048","DOI":"10.1016\/J.LFS.2022.121048","volume":"309","author":"SA Antar","year":"2022","unstructured":"Antar, S. A., Saleh, M. A., & Al-Karmalawy, A. A. (2022). Investigating the Possible Mechanisms of Pirfenidone to Be Targeted as a Promising Anti-Inflammatory, Anti-Fibrotic, Anti-Oxidant, Anti-Apoptotic, Anti-Tumor, and\/or Anti-SARS-CoV-2. Life Sciences, 309, 121048. https:\/\/doi.org\/10.1016\/J.LFS.2022.121048","journal-title":"Life Sciences"},{"key":"5919_CR8","doi-asserted-by":"publisher","unstructured":"Antar, S. A., Saleh, M. A., & Al-Karmalawy, A. A. (2022). Investigating the Possible Mechanisms of Pirfenidone to Be Targeted as a Promising Anti-Inflammatory, Anti-Fibrotic, Anti-Oxidant, Anti-Apoptotic, Anti-Tumor, and\/or Anti-SARS-CoV-2. Life Sciences, 309. https:\/\/doi.org\/10.1016\/j.lfs.2022.121048","DOI":"10.1016\/j.lfs.2022.121048"},{"key":"5919_CR9","doi-asserted-by":"publisher","first-page":"174503","DOI":"10.1016\/J.EJPHAR.2021.174503","volume":"911","author":"X Bai","year":"2021","unstructured":"Bai, X., Nie, P., Lou, Y., Zhu, Y., Jiang, S., Li, B., & Luo, P. (2021). Pirfenidone Is a Renal Protective Drug: Mechanisms, Signalling Pathways, and Preclinical Evidence. European Journal of Pharmacology, 911, 174503. https:\/\/doi.org\/10.1016\/J.EJPHAR.2021.174503","journal-title":"European Journal of Pharmacology"},{"key":"5919_CR10","doi-asserted-by":"publisher","unstructured":"Aimo, A., Cerbai, E., Bartolucci, G., Adamo, L., Barison, A., Lo Surdo, G., Biagini, S., Passino, C., & Emdin, M. (2020). Pirfenidone Is a Cardioprotective Drug: Mechanisms of Action and Preclinical Evidence. Pharmacological Research, 155. https:\/\/doi.org\/10.1016\/j.phrs.2020.104694","DOI":"10.1016\/j.phrs.2020.104694"},{"key":"5919_CR11","doi-asserted-by":"publisher","first-page":"170057","DOI":"10.1183\/16000617.0057-2017","volume":"26","author":"LH Lancaster","year":"2017","unstructured":"Lancaster, L. H., de Andrade, J. A., Zibrak, J. D., Padilla, M. L., Albera, C., Nathan, S. D., Wijsenbeek, M. S., Stauffer, J. L., Kirchgaessler, K. U., & Costabel, U. (2017). Pirfenidone Safety and Adverse Event Management in Idiopathic Pulmonary Fibrosis. European Respiratory Review, 26, 170057. https:\/\/doi.org\/10.1183\/16000617.0057-2017","journal-title":"European Respiratory Review"},{"key":"5919_CR12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1080\/0886022X.2021.1925297","volume":"43","author":"J Matsumoto","year":"2021","unstructured":"Matsumoto, J., Sunohara, K., Mori, Y., Nagaya, H., & Inaba, S. (2021). Effects of Pirfenidone on Renal Function in Patients with Interstitial Pneumonia. Renal Failure, 43, 879. https:\/\/doi.org\/10.1080\/0886022X.2021.1925297","journal-title":"Renal Failure"},{"key":"5919_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1183\/09059180.00008513","volume":"23","author":"M Kreuter","year":"2014","unstructured":"Kreuter, M., & Pirfenidone (2014). An Update on Clinical Trial Data and Insights from Everyday Practice. European Respiratory Review, 23, 111. https:\/\/doi.org\/10.1183\/09059180.00008513","journal-title":"European Respiratory Review"},{"key":"5919_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/NEP.13180","volume":"23","author":"V Diwan","year":"2018","unstructured":"Diwan, V., Brown, L., & Gobe, G. C. (2018). Adenine-Induced Chronic Kidney Disease in Rats. Nephrology, 23, 5\u201311. https:\/\/doi.org\/10.1111\/NEP.13180","journal-title":"Nephrology"},{"key":"5919_CR15","doi-asserted-by":"publisher","first-page":"2336128","DOI":"10.1080\/0886022X.2024.2336128","volume":"46","author":"Q Yang","year":"2024","unstructured":"Yang, Q., Su, S., Luo, N., & Cao, G. (2024). Adenine-Induced Animal Model of Chronic Kidney Disease: Current Applications and Future Perspectives. Renal Failure, 46, 2336128. https:\/\/doi.org\/10.1080\/0886022X.2024.2336128","journal-title":"Renal Failure"},{"key":"5919_CR16","doi-asserted-by":"publisher","unstructured":"Mobashar, A., Akbar, Z., Barkat, K., Hussain, K., Nadeem, H., Kharl, H. A. A., & Basri, M. A. (2025). Evaluation of Anti-Inflammatory and Anti-Arthritic Activities of Benzimidazole Derivative 2-((1H-Benzo [d] Imiadazol-2-Yl) Thio)-1-3, 5-Diphenyl-1\u00a0h-Pyrazol-1-Yl) Ethanone. Atlantic Journal of Life Sciences. https:\/\/doi.org\/10.71005\/z815ma53","DOI":"10.71005\/z815ma53"},{"key":"5919_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1046\/j.1523-1755.1998.00962.x","volume":"54","author":"T Shimizu","year":"1998","unstructured":"Shimizu, T., Kuroda, T., Hata, S., Fukagawa, M., Margolin, S. B., & Kurokawa, K. (1998). Pirfenidone Improves Renal Function and Fibrosis in the Post-Obstructed Kidney. Kidney international, 54, 99\u2013109.","journal-title":"Kidney international"},{"key":"5919_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1258\/EBM.2009.009214","volume":"235","author":"BH Ali","year":"2010","unstructured":"Ali, B. H., Al-Salam, S., Al Husseni, I., Kayed, R. R., Al-Masroori, N., Al-Harthi, T., Al Zaabi, M., & Nemmar, A. (2010). Effects of Gum Arabic in Rats with Adenine-Induced Chronic Renal Failure. Experimental biology and medicine (Maywood N J), 235, 373\u2013382. https:\/\/doi.org\/10.1258\/EBM.2009.009214","journal-title":"Experimental biology and medicine (Maywood N J)"},{"key":"5919_CR19","doi-asserted-by":"publisher","first-page":"W357","DOI":"10.1093\/NAR\/GKZ382","volume":"47","author":"A Daina","year":"2019","unstructured":"Daina, A., Michielin, O., Zoete, V., & SwissTargetPrediction (2019). Updated Data and New Features for Efficient Prediction of Protein Targets of Small Molecules. Nucleic Acids Research, 47, W357\u2013W364. https:\/\/doi.org\/10.1093\/NAR\/GKZ382","journal-title":"Nucleic Acids Research"},{"key":"5919_CR20","doi-asserted-by":"publisher","first-page":"D401","DOI":"10.1093\/NAR\/GKT1207","volume":"42","author":"M Kuhn","year":"2014","unstructured":"Kuhn, M., Szklarczyk, D., Pletscher-Frankild, S., Blicher, T. H., Von Mering, C., Jensen, L. J., & Bork, P. (2014). STITCH 4: Integration of Protein\u2013Chemical Interactions with User Data. Nucleic Acids Research, 42, D401\u2013D407. https:\/\/doi.org\/10.1093\/NAR\/GKT1207","journal-title":"Nucleic Acids Research"},{"key":"5919_CR21","doi-asserted-by":"publisher","unstructured":"Hu, Y., Guo, X., Yun, Y., Lu, L., Huang, X., & Jia, S. (2025). DisGeNet: A Disease-Centric Interaction Database among Diseases and Various Associated Genes. Database. https:\/\/doi.org\/10.1093\/DATABASE\/BAAE122","DOI":"10.1093\/DATABASE\/BAAE122"},{"key":"5919_CR22","doi-asserted-by":"publisher","first-page":"D1328","DOI":"10.1093\/NAR\/GKAE883","volume":"53","author":"AP Davis","year":"2025","unstructured":"Davis, A. P., Wiegers, T. C., Sciaky, D., Barkalow, F., Strong, M., Wyatt, B., Wiegers, J., McMorran, R., Abrar, S., & Mattingly, C. J. (2025). Comparative Toxicogenomics Database\u2019s 20th Anniversary: Update 2025. Nucleic Acids Research, 53, D1328\u2013D1334. https:\/\/doi.org\/10.1093\/NAR\/GKAE883","journal-title":"Nucleic Acids Research"},{"key":"5919_CR23","doi-asserted-by":"publisher","unstructured":"Oraibi, A. I., Karav, S., & Khallouki, F. (2025). Exploration of Rosmarinic Acid as Anti-Esophageal Cancer Potential by Use of Network Pharmacology and Molecular Docking Approaches. Atlantic Journal of Life Sciences. https:\/\/doi.org\/10.71005\/b5jben88","DOI":"10.71005\/b5jben88"},{"key":"5919_CR24","doi-asserted-by":"publisher","first-page":"W168","DOI":"10.1093\/NAR\/GKAD393","volume":"51","author":"JE Evangelista","year":"2023","unstructured":"Evangelista, J. E., Xie, Z., Marino, G. B., Nguyen, N., Clarke, D. J. B., & Ma\u2019Ayan, A. (2023). Enrichr-KG: Bridging Enrichment Analysis across Multiple Libraries. Nucleic Acids Research, 51, W168\u2013W179. https:\/\/doi.org\/10.1093\/NAR\/GKAD393","journal-title":"Nucleic Acids Research"},{"key":"5919_CR25","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/NAR\/GKW377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov, M. V., Jones, M. R., Rouillard, A. D., Fernandez, N. F., Duan, Q., Wang, Z., Koplev, S., Jenkins, S. L., Jagodnik, K. M., Lachmann, A., et al. (2016). Enrichr: A Comprehensive Gene Set Enrichment Analysis Web Server 2016 Update. Nucleic Acids Research, 44, W90. https:\/\/doi.org\/10.1093\/NAR\/GKW377","journal-title":"Nucleic Acids Research"},{"key":"5919_CR26","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/GR.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., Ideker, T., & Cytoscape (2003). A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Research, 13, 2498. https:\/\/doi.org\/10.1101\/GR.1239303","journal-title":"Genome Research"},{"key":"5919_CR27","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/NG.2653;SUBJMETA","volume":"45","author":"J Lonsdale","year":"2013","unstructured":"Lonsdale, J., Thomas, J., Salvatore, M., Phillips, R., Lo, E., Shad, S., Hasz, R., Walters, G., Garcia, F., Young, N. (2013). The Genotype-Tissue Expression (GTEx) Project. Nature Genetics 45, 580\u2013585, doi:https:\/\/doi.org\/10.1038\/NG.2653;SUBJMETA.","journal-title":"Nature Genetics"},{"key":"5919_CR28","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1074\/jbc.M607625200","volume":"282","author":"S Iyer","year":"2007","unstructured":"Iyer, S., Wei, S., Brew, K., & Acharya, K. R. (2007). Crystal Structure of the Catalytic Domain of Matrix Metalloproteinase-1 in Complex with the Inhibitory Domain of Tissue Inhibitor of Metalloproteinase-1. Journal of Biological Chemistry, 282, 364\u2013371. https:\/\/doi.org\/10.1074\/jbc.M607625200","journal-title":"Journal of Biological Chemistry"},{"key":"5919_CR29","doi-asserted-by":"publisher","unstructured":"Akib, T. I., Molla, I. H., Rishad, N., Rahman, L., Al Hasan, N., Tasmi, S. M., Shakil, M. M. R., & Islam, A. (2026). Integrated Bioinformatics and Machine Learning Analysis Identifies MT1F as a Potential Diagnostic Biomarker and Therapeutic Target in Breast Cancer. Atlantic Journal of Life Sciences. https:\/\/doi.org\/10.71005\/458kdy25","DOI":"10.71005\/458kdy25"},{"key":"5919_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/JCC.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O., Olson, A. J., AutoDock, & Vina (2010). Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization and Multithreading. Journal of computational chemistry, 31, 455. https:\/\/doi.org\/10.1002\/JCC.21334","journal-title":"Journal of computational chemistry"},{"key":"5919_CR31","doi-asserted-by":"publisher","first-page":"e10458","DOI":"10.34172\/NPJ.2022.10458","volume":"11","author":"S Ghodrati","year":"2022","unstructured":"Ghodrati, S., Haghi, Y. R., Baharani, J., Joseph, A., Alimohammadi, N., Koosha, F., Mostafavi, L., & Pezeshgi, A. (2022). Ameliorative Effects of Pirfenidone in Chronic Kidney Disease. Journal of Nephropharmacology, 11, e10458\u2013e10458. https:\/\/doi.org\/10.34172\/NPJ.2022.10458","journal-title":"Journal of Nephropharmacology"},{"key":"5919_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1517\/13543780903501539","volume":"19","author":"ME Cho","year":"2010","unstructured":"Cho, M. E., Kopp, J. B., & Pirfenidone (2010). An Anti-Fibrotic Therapy for Progressive Kidney Disease. Expert Opinion on Investigational Drugs, 19, 275\u2013283. https:\/\/doi.org\/10.1517\/13543780903501539","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"5919_CR33","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1681\/ASN.2008090931","volume":"20","author":"SP RamachandraRao","year":"2009","unstructured":"RamachandraRao, S. P., Zhu, Y., Ravasi, T., McGowan, T. A., Toh, I., Dunn, S. R., Okada, S., Shaw, M. A., & Sharma, K. (2009). Pirfenidone Is Renoprotective in Diabetic Kidney Disease. Journal of the American Society of Nephrology : JASN, 20, 1765\u20131775. https:\/\/doi.org\/10.1681\/ASN.2008090931","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"5919_CR34","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1681\/ASN.2010101049","volume":"22","author":"K Sharma","year":"2011","unstructured":"Sharma, K., Ix, J. H., Mathew, A. V., Cho, M., Pflueger, A., Dunn, S. R., Francos, B., Sharma, S., Falkner, B., McGowan, T. A., et al. (2011). Pirfenidone for Diabetic Nephropathy. Journal of the American Society of Nephrology : JASN, 22, 1144\u20131151. https:\/\/doi.org\/10.1681\/ASN.2010101049","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"5919_CR35","doi-asserted-by":"publisher","unstructured":"Lima-Posada, I., Fontana, F., P\u00e9rez-Villalva, R., Berman-Parks, N., & Bobadilla, N. A. (2019). Pirfenidone Prevents Acute Kidney Injury in the Rat. BMC nephrology, 20. https:\/\/doi.org\/10.1186\/S12882-019-1364-4","DOI":"10.1186\/S12882-019-1364-4"},{"key":"5919_CR36","doi-asserted-by":"publisher","unstructured":"Fois, A. G., Posadino, A. M., Giordo, R., Cossu, A., Agouni, A., Rizk, N. M., Pirina, P., Carru, C., Zinellu, A., & Pintus, G. (2018). Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients. Oxidative medicine and cellular longevity. https:\/\/doi.org\/10.1155\/2018\/2639081","DOI":"10.1155\/2018\/2639081"}],"container-title":["Applied Biochemistry and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-026-05919-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12010-026-05919-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-026-05919-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:15:44Z","timestamp":1792077344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12010-026-05919-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["5919"],"URL":"https:\/\/doi.org\/10.1007\/s12010-026-05919-z","relation":{},"ISSN":["0273-2289","1559-0291"],"issn-type":[{"value":"0273-2289","type":"print"},{"value":"1559-0291","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"10 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experimental procedures were approved by the Institutional Animal Ethics Committee (MUCM\/IAEC\/2025\/112) and were conducted in accordance with CPCSEA guidelines for the care and use of laboratory animals.","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the methods were performed in accordance with ARRIVE guidelines, laws, and regulations.","order":4,"name":"Ethics","label":"ARRIVE guidelines","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}